<div><div></div><div><span><p><span>Avalo Therapeutics, Inc. reported first-quarter 2026 results showing a wider comprehensive loss and net loss versus the prior-year quarter as the company increases spending to advance its clinical and regulatory programs.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current quarter</span></td><td><span>Prior year quarter</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>($19.7M)</span></td><td><span>($13.15M)</span></td><td><span>(49.9%)</span></td></tr><tr><td><span>Net income²</span></td><td><span>($19.63M)</span></td><td><span>($13.15M)</span></td><td><span>(49.3%)</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($0.98)</span></td><td><span>($1.25)</span></td><td><span>21.6%</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Comprehensive loss”. ² Reported as “Net loss”. ³ Reported as “loss per share of common stock, basic and diluted”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Clinical milestone: Positive Phase 2 LOTUS topline results in hidradenitis suppurativa (HS); primary endpoint met at both doses, supporting Phase 3 plans for abdakibart.</span></li><li><span>Pipeline strategy: Focus remains on advancing abdakibart toward registrational trials and evaluating additional indications and potential in‑licensing opportunities.</span></li><li><span>Operational scaling: R&amp;D and G&amp;A expenses increased to support pivotal preparations, manufacturing and clinical operations.</span></li><li><span>Capital position: Completed approximately $405M net follow‑on offering to fund operations and the Phase 3 program into 2029.</span></li></ul><p><span>Original SEC Filing: </span>Avalo Therapeutics, Inc. [ AVTX ] - 10-Q - May. 13, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

AVTX

<p>Avalo Therapeutics, Inc. reported its first-quarter 2026 results, showing a revenue of $19.7M and a net loss of $19.63M, reflecting a year-over-year decline in both metrics. The company achieved positive Phase 2 results for its drug abdakibart in treating hidradenitis suppurativa, supporting plans for Phase 3 trials. R&D and G&A expenses increased to prepare for pivotal trials, and the company completed a $405M follow-on offering to fund operations through 2029.</p>

TradingView

Avalo Therapeutics

SPDR S&P Biotech

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Blackrock Future Health ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Global Healthcare

VG Health

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

T. Rowe Price Health Care ETF

Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary